Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse - Research portal of Justus Liebig University Giessen:

Meeting Abstract

Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse

Authors list: Hartmann, F; Renner, C; Jung, W; Deisting, C; Trumper, L; Pfreundschuh, M

Publication year: 1995

Pages: 3243-3243

Journal: Blood

Volume number: 86

Issue number: 10, Suppl. 1

ISSN: 0006-4971

Conference: 37th Annual Meeting of the American Society of Hematology

Publisher: American Society of Hematology (ASH Publications)

Citation Styles

Harvard Citation style: Hartmann, F., Renner, C., Jung, W., Deisting, C., Trumper, L. and Pfreundschuh, M. (1995) Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse, Blood, 86(10, Suppl. 1), p. 3243

APA Citation style: Hartmann, F., Renner, C., Jung, W., Deisting, C., Trumper, L., & Pfreundschuh, M. (1995). Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse. Blood. 86(10, Suppl. 1), 3243.